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Adeno-associated virus (AAV) receptors range from heparan sulfate proteoglycan to sialic acid moieties
present on cell surfaces. Abundance of the glycan profiles is greatly influenced by animal species, cell type,
and culture conditions. The objective of this study was to determine whether AAV serotypes’ transduction
efficiencies specifically in the equine monolayer culture model are an accurate representation of
transduction efficiencies in tissue explants, a model more closely related to in vivo transduction. It was
found that AAV 2 and 2.5 transduced cells more efficiently in explants than in monolayers. Through
experiments involving assessing enzyme degradation of cell surface proteoglycans, this change could not be
attributed to differences in the extra cellular matrix (ECM), but a similar change in AAV 5 transduction
efficiency could be readily explained by differences in cell surface sialylated glycan. Unexpectedly it was
found that in a small but diverse sample of horses evidence for serum neutralizing antibodies was only found
to AAV 5. This suggests a unique relationship between this capsid and the equine host or an unresolved
relationship between similar bovine AAV and the AAV 5 capsid immune response.
G
ene therapy is currently being considered as a promising treatment for musculoskeletal diseases with
considerable emphasis placed on arthritis1–4. Intra-articular gene therapy would target tissue using a
vector that can infect articular cartilage and the synovial lining of the joint which contain the cell types
chondrocytes and synoviocytes, respectively5,6. Osteoarthritis is characterized in the joint by tissue wear particles
originating from the cartilage surface and increased inflammatory factors in the joint fluid7. Gene therapy has
focused on supplementation of anabolic factors including insulin-like growth factor-I, transforming growth
factor beta, bone morphogenetic protein 2, and inhibition of pro-inflammatory molecules using interleukin 4,
soluble tumor necrosis factor receptor, and interleukin-1 receptor antagonist protein which inhibits the pro-
inflammatory interleukin-13,8–12. Treatment with these biological molecules requires long term and steady state
dosing and both of these requirements are difficult to impossible using recombinant protein treatments but well
suited for the gene therapy approach5,13. Various viral vectors have been studied for gene therapy use in the joint
including herpes simplex virus, HIV based lentiviral vectors, adenovirus and adeno-associated virus (AAV)3,6,14,15.
Adeno-associated virus as a therapeutic vector currently shows the most promise as it can genetically modify a
variety of cells including non-dividing cells with minimal pathologic effects. As a result the gene of interest is
expressed long term, and tissue tropism is only limited by capsid serotype receptor accessibility2,16. The wide tissue
tropism partly comes from the existence of different serotypes, at least 12 of which have been described with over
100 variants in different animal species17–20.
One challenge facing AAV as a gene therapy vector is the prevalence of neutralizing antibodies found in the
patient population (.50% for AAV 2)21–24. The IgG antibodies from nonpathogenic AAV infections have been
proven to induce a neutralizing effect on AAV in vitro22. These antibodies drastically decrease the transduction
efficiency of the vector resulting in a treatment with limited to no success25. Due to the similarity between AAV
capsid serotypes and the cross reactivity antibodies can have to the capsid, the most effective assay that determines
transduction inhibition is a neutralization assay which directly tests whether the virus is not only bound by
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Cells in vitro are different in several ways from those in explants. A
cell monolayer typically results in certain cell types based on adher-
ence and growth conditions. Further cell passaging can induce ded-
ifferentiation and phenotypic changes as shown in chondrocytes26.
Exposure to cell surface and cell doubling is significantly different for
monolayer versus explants, all critical variables that may influence
vector transduction27. Many prior studies have been done with
monolayer cell cultures due to the simplicity and ability to better
control for variation in experiments. Because of the potential differ-
ences that may exist between transduction in monolayer and trans-
duction of cells in situ, our goal was to test whether cell monolayers
are a good approximation for transduction of tissue explant cultures.
The objective of this study was to determine whether transduction
efficiencies in the monolayer culture model are an accurate repres-
entation of transduction efficiencies in tissue explants, a model more
closely related to in vivo transduction. We hypothesized that there
may be differences in transduction efficiencies due to the increased
amount of extracellular matrix in explant tissues. Further, to max-
imize transduction efficiency in vivo we sought to investigate
whether neutralizing antibodies existed in the joint fluid or the serum
of the horse. We hypothesized that neutralizing antibodies would
most likely exist to some of the AAV serotypes that have efficient
transduction in equine synoviocytes and chondrocytes.
Results
Flow cytometry of vector transductions. Flow cytometry was
performed on monolayer and tissue explant cultures to analyze the
transduction efficiencies of AAV serotypes. The percentage of cells
transduced and expressing GFP provided an indication of the
proportion of the cells in the population that were permissive to an
AAV transduction. In brief, cartilage explants, synovium explants,
chondrocyte monolayers and synoviocyte monolayers were cultured
and transduced with AAVs 1, 2, 2.5, 3, 4, 5 and 6 at a dose of 8,000
virus particles per cell (VPC). All AAVs were self-complimentary
and encoded the gene for green fluorescent protein (GFP). This
allowed for the flow cytometric determination of which AAV
produced the highest percentage of cells expressing GFP, and
consequently which AAV was the most efficient at transducing the
cell type/culture of interest. The results divided AAV serotypes into
three classes based on preference for transducing explants or mono-
layers more efficiently: class I or those that transduced explants more
efficiently than monolayer, class II or those that showed no difference
between explant and monolayer transduction, and class III or those
that transduced monolayer more efficiently than explants. In
cartilage derived cultures class I consisted of AAV 2 and 2.5; class
II consisted of AAV 3 and 4; class III consisted of AAV 1, 5 and 6. In
cultures derived from synovium, class I consisted of AAV 1, 2, 2.5
and 6. Class II consisted of AAV 3, 4 and 5, and there were no
serotypes that could be categorized as class III (Figure 1). Flow
cytometry revealed AAV2 and 2.5 to be the most efficient
serotypes at transducing all tissue and culture types (Figure 2).
Between the two, AAV 2 was consistently more efficient than 2.5,
but this was not significant. AAV 3 was similar to 2 and 2.5 in all
cultures except for synovial explants and AAV 5 in all but synovial
and cartilage explants. AAV 1, 4 and 6 had varying amounts of
statistical similarity to the other serotypes but consistently
transduced cells the least efficiently of all serotypes. The difference
in transduction efficiencies between cartilage explants and chon-
drocyte monolayers is not significant while averaging across all
serotypes. This difference is significant however, when comparing
synovial explants and synoviocyte monolayers.
In a qualitative analysis of all the cultures (Figure 3 being a specific
example) AAV 2 consistently appeared to have the best overall trans-
duction efficiency. AAV 2.5 did not appear as efficient as the quant-
itative analysis showed. And finally AAV 1 and 4 often appeared to
not transduce cells at all, while AAV 3, 5 and 6 had mixed results but
usually presented transductions that were somewhat less efficient
than AAV 2.
Role of cell surface glycans. We next wished to compare the role of
cell surface receptors with serotype specific transduction in explants
versus monolayers. It was hypothesized that the differences in
transduction efficiencies between explants and monolayers seen in
Figure 1 could be attributed to varying concentrations of cell surface
receptors for AAV. A previous report28 indicated that lack of heparan
sulfate led to only a moderate decrease in AAV 2 transduction of
cells. While the previous report examined the role of heparan sulfate,
we also sought to determine the relationship of sialic acid (the other
primary receptor specific to AAV 1, 4, 5 and 6)29,30. An experiment
was performed where the primary cell surface receptors for AAV
were enzymatically cleaved and transduction efficiencies compared
to those of untreated controls. These experiments were carried out in
cell monolayer and joint tissue explants at 1000 VPC in the presence
of heparinase or neuraminidase. Enzyme treatment to remove cell
surface receptors for AAV 2 included heparinase I and III, AAV 2.5
included both heparinase I and III and neuraminidase III, and AAV 5
included neuraminidase III.
After enzyme treatment, there was no longer a statistical difference
in transduction efficiencies between synovial explant and synovio-
cyte monolayer for AAV 2 and 2.5. The enzyme treatment also
removed the statistical difference in transduction efficiencies
between cartilage explant and chondrocyte monolayer for AAV 5
transduction. Of note, enzyme treatment did not remove the statist-
ical difference in transduction efficiencies between cartilage explant
and chondrocyte monolayer for AAV 2 and 2.5. It was interesting to
note that AAV 2.5 is a rational design chimeric capsid containing 5
amino acids from AAV 1 spliced into the backbone of AAV 2 (ref.
31). While this capsid still utilizes heparan sulfate as the primary
receptor, the inclusion of the additional five amino acids plays a
Figure 1 | Comparison of transduction efficiencies within the same tissue
of origination but different culture types. The graphs show flow cytometry
analysis of the percent of cells transduced. Columns indicate mean percent
and bars indicate standard error of the mean. Asterisks denote a significant
difference between the explant and monolayer data in the specific AAV
serotype tested. P-values , 0.05 are considered significant.
www.nature.com/scientificreports
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significant but still unknown role in enhancing vector transduction
in muscle. AAV 2.5 was the first example of a chimeric AAV vector
used in a clinical trial31. The ability to mimic or partially mimic
successful in vivo transduction with joint tissue explants offers the
unique opportunity to exploit capsid library evolution that may con-
fer a syntropic capsid for the joint superior to any of the several
analyzed in this study.
Impact of neutralizing antibodies from equine serum and
synovial fluid on serotype transduction. We next sought to
understand the role of neutralizing antibodies. An experiment was
performed to determine the concentrations of serum and synovial
fluid that would prove to neutralize AAV transduction. In brief, serial
dilutions of serum or synovial fluid were created from 1512 to 15200
with incomplete F12 media as the diluent. The 1512 dilution would
Figure 2 | Ranking of AAV transduction efficiency as the percent of cells transduced in the cell and culture types tested. Columns indicate mean percent
and bars indicate standard error of the mean. Significance between serotypes is shown with letters. P-values , 0.05 are considered significant.
Figure 3 | Fluorescence micrographs of the cell and culture types tested showing the presence or not of AAV transduction with the vectors tested.
Pictures are from a single animal twelve days after transduction. From top row to bottom row: cartilage explants, chondrocyte monolayers, synovial
explants, and synoviocyte monolayers.
www.nature.com/scientificreports
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have the greatest concentration of serum or synovial fluid and
consequently neutralizing antibodies (if present). These concen-
trations were then pre-incubated with AAVGFP particles for one
hour prior to synoviocyte cell transduction. If neutralizing anti-
bodies were found in any treatment, this would have prevented the
AAVGFP particles from efficiently transducing the cells, resulting in
fewer cells expressing the GFP transgene as quantified by flow
cytometry measurement compared to a control transduction.
Specifically, any neutralizing serum or synovial fluid treatment was
recorded only if it inhibited at least half of the transduction compared
to the untreated, positive control. Additionally, as an increase in
concentration implies a commensurate increase in neutralizing
factors, only the lowest concentration dilution of serum or synovial
fluid was recorded as this would identify the minimum absolute
amount of neutralizing antibodies required to effect a 50% change
in transduction. This would additionally differentiate between the
strength of neutralization against specific serotypes. For example, if a
neutralizing concentration of 1525 was demonstrated, the stronger
concentration (1512) would also cause neutralization. And for
example, if neutralization at 15200 was found against AAV1 and
1525 against AAV2, this would imply a higher concentration and/
or greater specificity of antibodies to AAV1 than to AAV2. It was
found that no synovial fluid samples had neutralizing effects on AAV
transduction (Table 1). Serum samples were only neutralizing to
AAV 5 at the two highest concentrations tested and only to AAV 2
and 2.5 in one horse. Horses A and D were neutralizing to AAV 5 at a
1512 dilution while horses B and C were neutralizing at a 1525
dilution. Horse A was neutralizing to AAV 2 and 2.5 at only a
1512 dilution.
Discussion
Using GFP transduction and neutralization assays we demon-
strated differences between explant and monolayer transduction
efficiencies in the joint tissues of the horse using a wide range of
AAV serotypes. We observed three classes of AAV capsid trans-
duction. The varying preference with which AAV serotypes trans-
duce culture types was in agreement with findings by Mason
et al.32 The serotype most effective at transduction overall was
AAV 2. AAV 2.5, 3, 5 and 6 also were effective in varying culture
conditions. This is in agreement with work done in monolayer
cultures by Goodrich et al. that showed AAV 2, 3, 5 and 6 (AAV
2.5 was not included in the study) to be the most efficient sero-
types tested33. In this study we extended the above analyses to the
well-documented explant tissue model, previously shown to better
represent in vivo joint tissue and surface glycans34–36. AAV 6 was
found to be efficient in chondrocyte monolayers as in the previous
study but less efficient in cartilage explants. Of note, AAV 2 and
2.5 were more effective in explants while AAV 5 and 6 were more
effective in chondrocyte monolayers than in cartilage explants.
This would predict that AAV 2 and 2.5 would perform better in
vivo, all other variables being held constant. In fact, a recent study
analyzing AAV 2 and 2.5 demonstrated persistent (801 days) of
increased transgene expression (400 ng/ml) supporting our
explant studies37. The ability to mimic or partially mimic in vivo
success with joint tissue explants offers the unique opportunity to
exploit capsid library evolution that may offer syntropic capsids
that are superior to the collection analyzed in this study.
To address the differences between explants and monolayers, an
experiment was performed to enzymatically remove the cell surface
receptors for AAV and determine if this equalized the AAV trans-
duction efficiencies between the two. AAV 2 enzyme treatment
included heparinase I and III, AAV 2.5 included both heparinase I
and III and neuraminidase III, and AAV 5 included neuraminidase
III. AAV 2 uses the proteoglycan heparan sulfate as the major bind-
ing receptor, and human fibroblast growth factor receptor 1
(FGFR1), hepatocyte growth factor receptor (HGFR), and the integ-
rin avb5 as co-receptors38–41. It has been previously shown that AAV
2 transduction is not mediated by chondroitin sulfate moieties40.
Perlecan, however, has been theorized to be a binding site for AAV
based upon immunohistochemistry and a BLASTN search of AAV
Rep recognition sequences within the human genome42,43. AAV 5
uses the sialylated glycan a-2,3-N-linked sialic acid for the major
binding receptor44. AAV 2.5 is a chimera composed of AAV 2 with
5 amino acid substitutions from AAV 1 (which usesa-2,3- and a-2,6-
N-linked sialic acid as major receptors). The primary receptor is still
heparan sulfate and the role of the five amino acid substitutions is
unknown20,30. This experiment revealed that a difference in AAV 5
transduction efficiency between cartilage explant and chondrocyte
monolayer could be attributed to varying amounts of sialylated gly-
can. The difference in AAV 2 and 2.5 transduction efficiencies
between cartilage explant and chondrocyte monolayer cannot be
attributed to differences in heparin sulfate, and heparan sulfate or
sialylated glycan, respectively since removal of these receptors did
not reduce transduction. Finally, the difference between synovial
explant and synoviocyte monolayer transduction efficiencies for
AAV 2 and 2.5 can be explained by differences in heparan sulfate,
and heparan sulfate or sialylated glycan, respectively. For experi-
ments where changes in transduction efficiency between explants
and monolayers are not explained by differences in primary cell
surface receptors, there are several AAV secondary cell surface recep-
tors20,30 that could be contributing to the variable efficiencies. The
concentrations of enzymes used to remove cell surface glycans fol-
lowed the procedures by Shen et al. and were nearly 1000 times those
demonstrated to significantly reduce AAV transduction by
Summerford et al.40,45 In several cases, the results of the AAV trans-
ductions did not match the efficiencies from Figure 4. This could be
due to either using a lower titer of virus (which was necessary to
observe the effects of the enzyme) of 1000 VPC (as opposed to 8000
VPC) or the fact that the cells were analyzed at ten days (as opposed
to thirty). Although we expected a greater decrease in transduction in
the positive control, this degree of drop in transduction has been
reported in the past with this dose of viral particles per cell28. In
contrast, Summerford and Samulski found an 80% decrease in
rAAV transduction after heparinase treatment; however, this finding
used a viral dose of 2 VPC. The significantly higher dose of AAV used
in this study is hypothesized to have led to a smaller enzyme treat-
ment mediated decrease in transduction due to increased binding by
AAV to co-receptors HGFR, aVb5, and FGFR138,39,41. Lower viral
doses result in greater drops, however below 1000 viral particles per
cell in joint tissues results in very low transduction efficiencies37.
Regardless, it is of interest to determine if library select capsids with
joint tropism utilize sialic acid or heparan sulfate on combination
therapy.
Table 1 | Values for the minimum dilution of synovial fluid (SF) and
serum (‘‘SF/serum’’) at which neutralization of AAV was found. For
example, if a neutralizing concentration of 1525 was found, the
stronger concentrations (1512) would also cause neutralization.
‘‘-’’ indicates no statistically significant neutralization at any dilu-
tion. Neutralization is defined as the weakest concentration of syn-
ovial fluid or serum treatment giving a transduction statistically,
significantly less than 50% of the positive control (AAV treatment
with no synovial fluid or serum)
Virus Serotypes:
AAV2 AAV2.5 AAV3 AAV5 AAV6
Horse A: -/12 -/12 -/- -/12 -/-
Horse B: -/- -/- -/- -/25 -/-
Horse C: -/- -/- -/- -/25 -/-
Horse D: -/- -/- -/- -/12 -/-
www.nature.com/scientificreports
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There were several horses that demonstrated various levels of
AAV neutralization. All horses tested had no synovial fluid neutral-
ization to any serotype of AAV but serum neutralization of varying
degrees to AAV 5. Of note, bovine AAV shares capsid homology with
AAV 546. The dilutions of serum that proved neutralizing in our
study (1512 and 1525) could both be considered non-neutralizing
according to an arbitrary cutoff of 1550 that was used in the study by
Boissier et al., and the 1512 dilution could be considered non-neut-
ralizing by the cutoff of 1520 used in the study by Halbert et al21,24.
The cutoff established by Halbert et al indicated dilutions of less than
1520 can exhibit non-specific neutralization of AAV transduction,
meaning AAV is neutralized by factors other than antibodies specific
for the virus serotype. Horse A also revealed serum neutralization to
AAV 2 and 2.5 but only at the highest concentration and neither of
these neutralizations would be considered neutralizing by the pre-
vious cutoffs. There is known immune cross reactivity between ser-
otypes so this test cannot prove whether a specific neutralized AAV
serotype was responsible for a primary infection, if the neutralizing
capability of the serum is indeed due to pre-existing antibodies.
However, the experiment reveals that, in a clinical setting, it is favor-
able to use AAV 2, 2.5, 3 or 6 for gene therapy transduction in the
horse. Others could theoretically be used if neutralization is tested
before the gene therapy treatment. As neutralization was only seen in
the serum, it would be most accurate for testing to use serum rather
than synovial fluid for neutralization assays. This trend is in contrast
to the work of Cottard et al. which demonstrated a strong correlation
between serum and synovial fluid inhibition in humans22.
In conclusion, this study reveals that AAV transduction efficiency
can differ between explants and monolayers. One of the contributing
factors could be the increased amount of extracellular matrix found
in the explant. This suggests that monolayer cultures could provide
an adequate, relative model for testing transduction efficiency for
AAV serotypes in vivo, but explants may offer a more accurate
model. Additionally, we have shown there is a possibility of serum
neutralization to AAV 5 in some horses. This should encourage
clinicians to perform AAV 5 neutralization tests before administra-
tion of AAV gene therapy vectors to horses.
Methods
Transduction efficiencies. Tissues were harvested post mortem from four horses,
aged two to five years old, and euthanized for other reasons. Joints displayed no OA
pathology. Synovium was aseptically excised from the inside of the fetlock joint
capsule and cartilage from the patella. Similarly sized explants approximating 5 mm
squares were cut from the larger pieces and kept in wells of 48 well plates with 500 mL
Ham’s F12 media (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine
serum (Sigma-Aldrich, St. Louis, MO, USA), 13 antibiotic antimycotic (HyClone,
Logan, UT, USA), and 1N HEPES buffer (Invitrogen) changed every other day. The
remaining synovium and cartilage pieces were diced and digested as previously
described47. Cells were plated in appropriately sized tissue culture flasks at a density of
100,000/cm2 for synoviocytes and 200,000/cm2 for chondrocytes. Cells were grown
for four days, then trypsinized and replated in 48 well plates at the aforementioned
plating density. Two days following plating, cells and explants were transduced with
scAAV-eGFP serotypes 1, 2, 2.5, 3, 4, 5 and 6 from the Gene Therapy Center Vector
Core Facility (Chapel Hill, NC, USA). The vector scAAV-eGFP (pHpa-trs-SK)
construct and cross packaging has been described previously48,49. Transduction was
preceded by rinsing cells in PBS and then 250 mL Ham’s F12 media was put into the
wells. scAAV-eGFP was added to the wells at a concentration of 8000 virus particles
per cell (VPC). The virus incubated with the cells for four hours at 37uC and 5% CO2
and was then aspirated and replaced by complete F12 media. The day of transduction
was considered day zero. On days 4, 8, 12, 16, and 20, fluorescent microscopy pictures
were taken of the cells and explants. The microscope used was an Olympus IX70
(Center Valley, PA, USA) with a filter cube with excitation at 495 nm and emission at
521 nm and at 1003 magnification. Software used to capture images was QCapture
by QImaging (Surrey, BC, Canada) and no post processing occurred. On day thirty,
explants were individually digested and plated immediately into wells according to
the prior digestion protocol. The explant cells adhered to the well for two days and
then all wells were trypsinized. PBS with 0.2% FBS was added and the suspension
analyzed by flow cytometry. Suspensions were run through a CyAn ADP Analyzer
(Beckman Coulter, Brea, California, USA) and data analyzed with Summit 4.3
software (Dako, Carpinteria, CA, USA). The percent of cells transduced was the final
data set analyzed. A mixed model ANOVA was used with horses being considered
random variables. Statistics were considered significant with a p-value , 0.05.
Enzymatic desialylation and AAV transduction. Explants of cartilage and
synovium and monolayers of chondrocytes and synoviocytes were isolated from a
horse as described prior. Cultures were treated with heparinase I and III (Sigma-
Aldrich #H2519 and #H8891, respectively) and/or neuraminidase III (Sigma-Aldrich
#N7885) as described45. Briefly, cultures were treated with 3 U/ml heparinase I,
1.5 U/ml heparinase III, and/or 50 mU/ml neuraminidase in incomplete Ham’s F12
media for two hours at 37uC and 5% CO2. Cultures were rinsed and scAAV-eGFP of
1000 VPC was added in incomplete Ham’s F12 media and incubated for four hours at
37uC and 5% CO2. The lower level of 1000 VPC was shown to produce a more
noticeable difference between enzyme treated and control samples as similarly found
previously28. Finally, the virus suspension was removed and complete Ham’s F12
Figure 4 | Comparison of AAV transduction rates as percent of cells transduced in cultures treated with heparinases I and III (for AAV 2 and 2.5) and
neuraminidase (for AAV 2.5 and 5). Positive controls are denoted with dark fill and enzyme groups with light fill. Asterisks denote a significant difference
between the enzyme treated and control group of the specific cell, culture, and virus type tested. ‘‘-----’’ denotes a significant difference between
enzymatically treated explant and monolayer cells of the same derived tissue within the specific serotype.
www.nature.com/scientificreports
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media was added. At seven days post transduction the explants were digested and
plated as previously described. On day ten the cells were analyzed with flow cytometry
as described above. A fixed effects ANOVA was used for statistical analysis and
significance was established at a p-value , 0.05.
AAV neutralizing antibodies. Synovial fluid and serum were collected post mortem
from four horses euthanized for other reasons, and independent to the horses prior.
293 cells were plated and grown in Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen) supplemented as described above in 48-well plates to act as an indicator of
AAV neutralization. Two days after plating, synovial fluid and serum dilutions of
1512, 1525, 1550, 15100 and 15200 were created from the four animals with
incomplete DMEM media. To the dilutions were added 8000 VPC of scAAV-eGFP
serotypes 2, 2.5, 3, 5 and 6. The virus and serum or synovial fluid dilutions were
incubated at 37uC and 5% CO2 for one hour. Following this incubation the mixtures
were used in a four hour transduction of 293 cells. Post transduction the mixtures
were replaced with complete DMEM. Six days post transduction the cells were
analyzed with flow cytometry as described above. Neutralization was defined as a
concentration of synovial fluid or serum that inhibited a transduction by at least 50%
compared to the positive control (AAV treatment with no synovial fluid or serum).
Only the neutralizing dilution with the weakest concentration of synovial fluid or
serum was indicated for each combination of treatment type and serotype. Statistical
analysis was performed using a fixed effects ANOVA, and significance was
established at a p-value , 0.05.
1. Ghivizzani, S. C. et al. Direct adenovirus-mediated gene transfer of interleukin 1
and tumor necrosis factor alpha soluble receptors to rabbit knees with
experimental arthritis has local and distal anti-arthritic effects. Proc. Natl. Acad.
Sci. U.S.A 95, 4613–4618 (1998).
2. Evans, C. H., Gouze, J. N., Gouze, E., Robbins, P. D. & Ghivizzani, S. C.
Osteoarthritis gene therapy. Gene Ther. 11, 379–389, doi:10.1038/sj.gt.3302196
(2004).
3. Goodrich, L. R. et al. Direct adenovirus-mediated IGF-I gene transduction of
synovium induces persisting synovial fluid IGF-I ligand elevations. Gene Ther. 13,
1253–1262, doi:10.1038/sj.gt.3302757 (2006).
4. Goodrich, L. R., Hidaka, C., Robbins, P. D., Evans, C. H. & Nixon, A. J. Genetic
modification of chondrocytes with insulin-like growth factor-1 enhances cartilage
healing in an equine model. J. Bone Joint Surg. Br. 89B, 672–685, doi:10.1302/
0301-620x.89b5.18343 (2007).
5. Watanabe, S. et al. Adeno-associated virus mediates long-term gene transfer and
delivery of chondroprotective IL-4 to murine synovium. Mol. Ther. 2, 147–1
(2000).
6. Madry, H., Cucchiarini, M., Terwilliger, E. F. & Trippel, S. B. Recombinant adeno-
associated virus vectors efficiently and persistently transduce chondrocytes in
normal and osteoarthritic human articular cartilage. Hum. Gene Ther. 14,
393–402 (2003).
7. Goldring, S. R. & Goldring, M. B. The role of cytokines in cartilage matrix
degeneration in osteoarthritis. Clin. Orthop. Relat. Res. S27–S36, doi:10.1097/
01.blo.0000144854.66565.8f (2004).
8. Frisbie, D. D., Ghivizzani, S. C., Robbins, P. D., Evans, C. H. & McIlwraith, C. W.
Treatment of experimental equine osteoarthritis by in vivo delivery of the equine
interleukin-1 receptor antagonist gene. Gene Ther. 9, 12–20 (2002).
9. Glansbeek, H. L., van Beuningen, H. M., Vitters, E. L., van der Kraan, P. M. & van
den Berg, W. B. Stimulation of articular cartilage repair in established arthritis by
local administration of transforming growth factor-beta into murine knee joints.
Lab. Invest. 78, 133–142 (1998).
10. Glansbeek, H. L. et al. Bone morphogenetic protein 2 stimulates articular cartilage
proteoglycan synthesis in vivo but does not counteract interleukin-1 alpha effects
on proteoglycan synthesis and content. Arthritis Rheum. 40, 1020–1028,
doi:10.1002/art.1780400605 (1997).
11. Lubberts, E. et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17
and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest. 105,
1697–1710 (2000).
12. Kim, S. H. et al. Ex Vivo Gene Delivery of IL-1Ra and Soluble TNF Receptor
Confers a Distal Synergistic Therapeutic Effect in Antigen-Induced Arthritis. Mol.
Ther. 6, 591–600 (2002).
13. Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. Getting arthritis gene therapy into
the clinic. Nat. Rev. Rheumatol. 7, 244–249, doi:10.1038/nrrheum.2010.193
(2011).
14. Oligino, T. et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene
vector reduces inflammation in a rabbit model of arthritis. Gene Ther. 6,
1713–1720 (1999).
15. Gouze, E. et al. In vivo gene delivery to synovium by lentiviral vectors. Mol. Ther.
5, 397–404, doi:10.1006/mthe.2002.0562 (2002).
16. Ulrich-Vinther, M. Gene therapy methods in bone and joint disorders -
Evaluation of the adeno-associated virus vector in experimental models of
articular cartilage disorders, periprosthetic osteolysis and bone healing. Acta
Orthop. 78, 5–64 (2007).
17. Choi, V. W., McCarty, D. M. & Samulski, R. J. AAV hybrid serotypes: Improved
vectors for gene delivery. Curr. Gene Ther. 5, 299–310 (2005).
18. Schmidt, M. et al. Adeno-associated virus Type 12 (AAV12): A novel AAV
serotype with sialic acid- and heparan sulfate proteoglycan-independent
transduction activity. J. Virol. 82, 1399–1406, doi:10.1128/jvi.02012-07 (2008).
19. Gao, G. P., Vandenberghe, L. H. & Wilson, J. M. New recombinant serotypes of
AAV vectors. Curr. Gene Ther. 5, 285–297 (2005).
20. Wu, Z. J., Asokan, A. & Samulski, R. J. Adeno-associated virus serotypes: Vector
toolkit for human gene therapy. Mol. Ther. 14, 316–327, doi:10.1016/
j.ymthe.2006.05.009 (2006).
21. Halbert, C. L. et al. Prevalence of Neutralizing Antibodies Against Adeno-
Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal
Populations: Implications for Gene Therapy Using AAV Vectors. Hum. Gene
Ther. 17, 440–447, doi:10.1089/hum.2006.17.440 (2006).
22. Cottard, V. et al. Immune response against gene therapy vectors: Influence of
synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes.
J. Clin. Immunol. 24, 162–169 (2004).
23. Boutin, S. et al. Prevalence of Serum IgG and Neutralizing Factors Against Adeno-
Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population:
Implications for Gene Therapy Using AAV Vectors. Hum. Gene Ther. 21,
704–712, doi:10.1089/hum.2009.182 (2010).
24. Boissier, M. C. et al. Synoviocyte infection with adeno-associated virus (AAV) is
neutralized by human synovial fluid from arthritis patients and depends on AAV
serotype. Hum. Gene Ther. 18, 525–535, doi:10.1089/hum.2006.174 (2007).
25. Scallan, C. D. et al. Human immunoglobulin inhibits liver transduction by AAV
vectors at low AAV2 neutralizing titers in SCID mice. Blood 107, 1810–1817,
doi:10.1182/blood-2005-08-3229 (2006).
26. Lin, Z. et al. Gene expression profiles of human chondrocytes during passaged
monolayer cultivation. J. Orthop. Res. 26, 1230–1237, doi:10.1002/jor.20523
(2008).
27. Alexander, I. E., Russell, D. W., Spence, A. M. & Miller, A. D. Effects of gamma
irradiation on the transduction of dividing and nondividing cells in brain and
muscle of rats by adeno-associated virus vectors. Hum. Gene Ther. 7, 841–850
(1996).
28. Boyle, M. et al. Membrane-associated heparan sulfate is not required for rAAV-2
infection of human respiratory epithelia. Virology 3, 29 (2006).
29. Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J. & Chiorini, J. A. Adeno-
Associated Virus Serotype 4 (AAV4) and AAV5 Both Require Sialic Acid Binding
for Hemagglutination and Efficient Transduction but Differ in Sialic Acid Linkage
Specificity. J. Virol. 75, 6884–6893, doi:10.1128/jvi.75.15.6884-6893.2001 (2001).
30. Wu, Z. J., Miller, E., Agbandje-McKenna, M. & Samulski, R. J. alpha 2,3 and alpha
2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-
associated virus types 1 and 6. J. Virol. 80, 9093–9103, doi:10.1128/jvi.00895-06
(2006).
31. Bowles, D. E. et al. Phase 1 Gene Therapy for Duchenne Muscular Dystrophy
Using a Translational Optimized AAV Vector. Mol. Ther. 20, 443–455, doi:http://
www.nature.com/mt/journal/v20/n2/suppinfo/mt2011237s1.html (2012).
32. Mason, J. B., Vandenberghe, L. H., Xiao, R., Wilson, J. M. & Richardson, D. W.
Influence of serotype, cell type, tissue composition, and time after inoculation on
gene expression in recombinant adeno-associated viral vector–transduced equine
joint tissues. Am. J. Vet. Res. 73, 1178–1185, doi:10.2460/ajvr.73.8.1178 (2012).
33. Goodrich, L. R., Choi, V. W., Carbone, B. A. D., McIlwraith, C. W. & Samulski,
R. J. Ex Vivo Serotype-Specific Transduction of Equine Joint Tissue by Self-
Complementary Adeno-Associated Viral Vectors. Hum. Gene Ther. 20,
1697–1702, doi:10.1089/hum.2009.030 (2009).
34. Collier, S. & Ghosh, P. Effects of transforming growth factor beta on proteoglycan
synthesis by cell and explant cultures derived from the knee joint meniscus.
Osteoarthr. Cartilage 3, 127–138, doi:http://dx.doi.org/10.1016/S1063-
4584(05)80045-7 (1995).
35. Flannery, C. R., Little, C. B., Caterson, B. & Hughes, C. E. Effects of culture
conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the
expression of matrix metalloproteinases (MMPs) and disintegrin
metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol. 18,
225–237, doi:http://dx.doi.org/10.1016/S0945-053X(99)00024-4 (1999).
36. Collier, S. & Ghosh, P. Comparison of the effects of non-steroidal anti-
inflammatory drugs (NSAIDs) on proteoglycan synthesis by articular cartilage
explant and chondrocyte monolayer cultures. Biochem. Pharmacol. 41,
1375–1384, doi:http://dx.doi.org/10.1016/0006-2952(91)90111-H (1991).
37. Goodrich, L. R. et al. Optimization of scAAVIL-1ra In Vitro and In Vivo to
Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol.
Ther. Nucleic Acids 2, e70, doi:10.1038/mtna.2012.61 (2013).
38. Kashiwakura, Y. et al. Hepatocyte Growth Factor Receptor Is a Coreceptor for
Adeno-Associated Virus Type 2 Infection. J. Virol. 79, 609–614, doi:10.1128/
jvi.79.1.609-614.2005 (2005).
39. Summerford, C., Bartlett, J. S. & Samulski, R. J. alpha V beta 5 integrin: a co-
receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78–82 (1999).
40. Summerford, C. & Samulski, R. J. Membrane-associated heparan sulfate
proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72,
1438–1445 (1998).
41. Qing, K. et al. Human fibroblast growth factor receptor 1 is a co-receptor for
infection by adeno-associated virus 2. Nat. Med. 5, 71–77 (1999).
42. Konishi, M., Kawamoto, K., Izumikawa, M., Kuriyama, H. & Yamashita, T. Gene
transfer into guinea pig cochlea using adeno-associated virus vectors. J. Gene Med.
10, 610–618, doi:10.1002/jgm.1189 (2008).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5861 | DOI: 10.1038/srep05861 6
43. Wonderling, R. S. & Owens, R. A. Binding sites for adeno-associated virus rep
proteins within the human genome. J. Virol. 71, 2528–2534 (1997).
44. Walters, R. W. et al. Binding of Adeno-associated Virus Type 5 to 2,3-Linked Sialic
Acid Is Required for Gene Transfer. J. Biol. Chem. 276, 20610–20616, doi:10.1074/
jbc.M101559200 (2001).
45. Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H. & Asokan, A. Terminal N-
Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9. J. Biol.
Chem. 286, 13532–13540, doi:10.1074/jbc.M110.210922 (2011).
46. Johnson, F. B., Fenn, L. B., Owens, T. J., Faucheux, L. J. & Blackburn, S. D.
Attachment of bovine parvovirus to sialic acids on bovine cell membranes. J. Gen.
Virol. 85, 2199–2207, doi:10.1099/vir.0.79899-0 (2004).
47. Nixon, A. J., Lust, G. & Verniersinger, M. Isolation, propogation, and
cryopreservation of equine articular chondrocytes. Am. J. Vet. Res. 53, 2364–2370
(1992).
48. McCarty, D. M., Monahan, P. E. & Samulski, R. J. Self-complementary
recombinant adeno-associated virus (scAAV) vectors promote efficient
transduction independently of DNA synthesis. Gene Ther. 8, 1248–1254 (2001).
49. Rabinowitz, J. E. et al. Cross-packaging of a single adeno-associated virus (AAV)
type 2 vector genome into multiple AAV serotypes enables transduction with
broad specificity. J. Virol. 76, 791–801, doi:10.1128/jvi.76.2.791-801.2002 (2002).
Acknowledgments
This work was conducted with support from NIH grant K08AR054903 (Goodrich,
McIlwraith, Samulski), 1R01DK084033 (Samulski) 2-R01-AI072176-06A1 (Samulski) P01
HL112761-01A1 (Samulski) and a grant from the Colorado State University College
Research Council (Hemphil, Goodrich). We would like to acknowledge the Gene Therapy
Center Vector Core at the University of North Carolina at Chapel Hill for providing the
scAAV-eGFP vectors of all serotypes.
Author contributions
D.D.H. wrote the main manuscript. D.D.H., C.W.M., R.J.S. and L.R.G. reviewed the
manuscript.
Additional information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Hemphill, D.D., McIlwraith, C.W., Samulski, R.J. & Goodrich, L.R.
Adeno-Associated Viral Vectors Show Serotype Specific Transduction of Equine Joint
Tissue Explants and Cultured Monolayers. Sci. Rep. 4, 5861; DOI:10.1038/srep05861
(2014).
This work is licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 4.0 International License. The images or other third party material in
this article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder
in order to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5861 | DOI: 10.1038/srep05861 7
